Posted on August 15, 2011 by Sitemaster
We have reported on a number of attempts to use tyrosine kinase inhibitors (TKIs) — alone or in combination with chemotherapy — in the treatment of men with castration-resistant prostate cancer (CRPC). Limited activity or efficacy has been reported to date. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: bicalutamide, castration-resistant, CRPC, metastatic, sorefanib, TKI, tyrosine kinase inhibitor | Leave a comment »
Posted on March 10, 2011 by Sitemaster
One of the great unanswered questions (so far) is whether adding a tyrosine kinase inhibitor (a TKI) to docetaxel + prednisone can improve outcomes for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: castration-resistant, cediranib, mCRPC, metastatic, TKI, tyrosine kinase inhibitor | Leave a comment »
Posted on January 19, 2010 by Sitemaster
Like many other drugs before it, lapatinib (Tykerb/GlaxoSmithKline) appears to have very limited clinical activity in prostate cancer according to a recently published report. … READ MORE …
Filed under: Drugs in development | Tagged: lapatinib, Tykerb, tyrosine kinase inhibitor | 2 Comments »
